Policy Watch: 27 Regulatory Updates — March 16, 2026

Schedules of Controlled Substances: Temporary Placement of Bromazolam in Schedule I

Regulatory Summary This DEA action temporarily schedules bromazolam (a benzodiazepine analog) as a controlled substance, relevant to cannabis clinicians managing concurrent sedative use and potential drug interactions with cannabinoid therapies.

Schedules of Controlled Substances: Placement of Butonitazene, Flunitazene, and Metodesnitazene in Schedule I

This DEA scheduling action addresses synthetic opioids, not cannabis, and has no direct relevance to cannabis medicine practitioners or patients.

Schedules of Controlled Substances: Placement of Ethylphenidate in Schedule I

Regulatory Summary This action schedules ethylphenidate as a controlled substance, which has no direct clinical relevance to cannabis medicine practitioners or patients, as it addresses a different pharmaceutical compound.

Schedules of Controlled Substances: Temporary Placement of N-pyrrolidino metonitazene and N-pyrrolidino protonitazene in Schedule I

This regulatory action schedules synthetic opioids but does not directly affect cannabis medicine; however, clinicians should note potential drug interaction concerns when treating patients using both cannabis and scheduled substances.

Importer of Controlled-Biopharmaceutical(2024-20085)DEA1425

Regulatory Summary DEA registration 2024-20085 authorizes pharmaceutical importation of controlled biopharmaceuticals, potentially affecting cannabis clinicians’ access to standardized cannabinoid-derived medications and research compounds.

Schedules of Controlled Substances: Temporary Placement of N-Desethyl Isotonitazene and N-Piperidinyl Etonitazene in Schedule I

Regulatory Summary The DEA temporarily placed two synthetic opioids in Schedule I, establishing legal precedent for emergency substance scheduling that cannabis clinicians should monitor regarding potential future cannabis-derived compound regulations.

Schedules of Controlled Substances: Rescheduling of Marijuana

Regulatory Summary The DEA proposes reclassifying marijuana from Schedule I to Schedule III, potentially enabling medical research, reducing criminal penalties, and improving patient access while maintaining federal oversight of cannabis therapeutics.

Definition of Engaged in the Business as a Dealer in Firearms

This firearms regulation is not directly relevant to cannabis clinicians or patients, as it addresses dealer licensing requirements unrelated to cannabis medicine practice or patient care.

Schedules of Controlled Substances: Placement of Etodesnitazene, N-Pyrrolidino etonitazene, and Protonitazene in Schedule I

This regulation places three synthetic opioids in Schedule I; it is not directly relevant to cannabis clinicians or patients as it concerns different controlled substances.

Schedules of Controlled Substances: Placement of Butonitazene, Flunitazene, and Metodesnitazene Substances in Schedule I

This DEA action schedules three synthetic opioids (butonitazene, flunitazene, metodesnitazene) as controlled substances, relevant to cannabis clinicians managing pain patients who may use or consider alternative analgesics.

Schedules of Controlled Substances: Placement of 2-Methyl AP-237 in Schedule I

The DEA placed 2-Methyl AP-237 in Schedule I, classifying it as a controlled substance with no accepted medical use; this action does not directly affect cannabis clinical practice or patient care.

Schedules of Controlled Substances: Placement of 2,5-dimethoxy-4-iodoamphetamine and 2,5-dimethoxy-4-chloroamphetamine in Schedule I

This regulatory action schedules synthetic amphetamines (DOI and DOC) as Schedule I controlled substances, with minimal direct relevance to cannabis medicine practice or patient care.

Schedules of Controlled Substances: Temporary Placement of MDMB–4en–PINACA, 4F–MDMB–BUTICA, ADB–4en–PINACA, CUMYL–PEGACLONE, 5F–EDMB–PICA, and MMB–FUBICA into Schedule I

Regulatory Summary The DEA temporarily placed six synthetic cannabinoids into Schedule I, restricting their availability and establishing legal prohibitions relevant to cannabis medicine practitioners and patients seeking regulated alternatives.

Schedules of Controlled Substances: Placement of Ethylphenidate in Schedule I

Regulatory Summary This action schedules ethylphenidate (a stimulant) as a controlled substance, establishing regulatory precedent for drug scheduling that may inform future cannabis reclassification discussions and treatment protocol considerations for clinicians.

Schedules of Controlled Substances: Placement of Metonitazene in Schedule I

This regulatory item addresses metonitazene scheduling and has no direct relevance to cannabis clinicians or patients, as metonitazene is a synthetic opioid unrelated to cannabis medicine.

Schedules of Controlled Substances: Temporary Placement ofEtizolam, Flualprazolam, Clonazolam, Flubromazolam, and Diclazepam in Schedule I

This regulation temporarily schedules five benzodiazepine analogs as controlled substances, relevant to cannabis clinicians who may consider benzodiazepines for anxiety management in cannabis patients or monitor drug interactions.

Importer of Controlled Substances Application Biopharmaceutical Research Company – DEA1224

Regulatory Summary This DEA application permits a biopharmaceutical research company to import controlled substances, including cannabis-derived compounds, enabling clinical research and development of cannabis-based medicines.

Importer of Controlled-Bright Green(2024-20083)DEA1426

Regulatory Summary DEA permit (2024-20083) authorizes importation of controlled substances including cannabis; clinicians and patients should verify supplier DEA registration compliance for legal medication access.

Importer of Controlled-Cambridge Isotope(2024-20082)DEA1429

Regulatory Summary DEA registration (2024-20082) permits Cambridge Isotope to import controlled substances, potentially enabling production of isotopically-labeled cannabis research compounds for clinical studies and therapeutic development.

Medicare and Medicaid Programs: Calendar Year 2025 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; etc.

CMS establishes 2025 Medicare payment policies and coverage determinations for Part B services; cannabis clinicians should monitor for any coverage changes affecting cannabinoid treatments or consultation reimbursement rates.

Medicare and Medicaid Programs; CY 2025 Payment Policies under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; Medicare Prescription Drug Inflation Rebate Program (CMS-1807-P)

Regulatory Summary CMS updates 2025 Medicare Part B payment policies and coverage rules, which may affect cannabis medicine reimbursement and clinical practice standards for qualified practitioners treating Medicare beneficiaries.

Bulk Manufacturer-Royal Emerald (2024-11786) DEA1368

Regulatory Summary DEA approval for Royal Emerald bulk manufacturer license (2024-11786) establishes licensed cannabis production capacity, directly affecting clinician access to standardized cannabis products and patient medication availability.

Importer Controlled-VA Cooperative (2024-11795) DEA1374

Regulatory Summary The DEA’s Importer Controlled-VA Cooperative designation establishes import protocols for controlled substances, directly affecting cannabis clinicians’ and patients’ access to federally regulated cannabis-derived medications and research materials.

Importer Controlled- Quagen Pharma (2024-11892) DEA1381

Regulatory Summary DEA Form 1381 import control action for Quagen Pharma indicates monitoring of controlled substance importation procedures relevant to cannabis clinicians managing drug interactions and regulatory compliance.

Exempt Chemical Preparations May 2024 (2024-10465) – DEA372

The DEA updated exempt chemical preparations guidance in May 2024, clarifying which cannabis-derived compounds and preparations may qualify for regulatory exemptions, affecting prescribing practices and patient access.

Medicare and Medicaid Programs; CY 2024 Payment Policies under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; Continued Implementation of Requirements for Manufacturers of Certain Single-dose Container or Single-use Package Drugs to Provide Refunds with Respect to Discarded Amounts; Medicare Advantage (CMS-1784-F)

This final rule establishes Medicare Part B payment policies for 2024; cannabis clinicians should monitor coverage determinations as cannabis remains federally non-covered, though state programs may reference these payment methodologies.

Medicare and Medicaid Programs; CY 2024 Payment Policies under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; Continued Implementation of Requirements for Manufacturers of Certain Single-dose Container or Single-use Package Drugs to Provide Refunds with Respect to Discarded Amounts; Medicare Advantage (CMS-1784-P)

This CMS regulation establishes Medicare payment policies and coverage rules for 2024; cannabis clinicians should monitor whether cannabis products gain coverage status or payment coding changes affecting patient access and reimbursement.

Clinical Perspective on DEA Scheduling Actions These notices primarily document the Drug Enforcement Administration’s systematic placement of novel synthetic opioids and designer drugs into Schedule I, reflecting an ongoing regulatory response to emerging substances of abuse that are not yet widely integrated into established treatment or medical practice. The predominance of nitazene analogs and synthetic cannabinoids in these scheduling actions suggests clinicians should remain alert to evolving drugs of abuse, particularly novel opioids that may present with unfamiliar toxidromes and limited antidote efficacy compared to traditional opioid overdoses. From a clinical standpoint, these regulatory actions serve as early warning signals that new psychoactive substances are entering the illicit market and warrant familiarity among emergency medicine and addiction medicine providers.